ABOUT CELLTRION

About Us . A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. GENERIC CELLTRION PROJECT Efficiency improved through intra-group cooperation. For the success of the GCP, Celltrion Group has divided the tasks across two divisions. Celltrion Generic Business Division presides over the overall project, while Celltrion Pharm is responsible for research and production functions. DIATRUST™ COVID-19 AG RAPID TEST Celltrion DiaTrust™ COVID-19 Ag Rapid Test is a rapid test based on lateral flow immunoassay intended for the qualitative detection of nucleocapsid and receptor binding domains (RBDs) from the SARS-CoV-2 spike proteins in human nasopharyngeal swab specimen.

PERFORMANCE

보도자료 목록; Title Attached file Registration date; 1Q 2021 Earnings Release_Celltrion Inc. 2021.05.12: FY2020, 4Q20 Earning Release_Celltrion Inc.

DIATRUST™

Celltrion DiaTrust™ COVID-19 IgG/IgM Rapid Test is an in vitro diagnostic test based on an immunochromatographic assay. It is designed for qualitative detection of Immunoglobulin G and Immunoglobulin M antibodies of the novel Coronavirus (COVID-19) in PIPELINE | CELLTRION Celltrion will continue to blaze new trails and discover new opportunities. Project INN Original Major Indications Status Clinical Info; CT-P39: Omalizumab

SAMPINUTE™

Sampinute™ Analyzer (Immunoassay analyzer) Sampinute™ Analyzer detects specific biomarkers via immunoassay (MESIA; Magnetic Electrochemical Sandwich lmmunoassay) from a small amount of test sample. Sampinute™ Analyzer is intended to be used as an in vitro diagnostic medical device. Please read the user manual thoroughly for correct use and keep it for future reference.

INVESTOR INQUIRIES

1. General Statement . Celltrion, Inc. ("we", "us", "our" or "Celltrion") is committed to protecting and respecting your personal data. In the event that you send us any of your personal data, we are committed to collecting, maintaining, and securing personal data about you in accordance with our internal data protection policies and local

laws.

PRESS RELEASE

Celltrion DiaTrust™ COVID-19 Ag Rapid Test - Available for immediate supply - Expanded usage scope for use at the Point of Care(POC) and serial testing programs - Promising test sensitivity for COVID-19 variants with clinical data showing equivalent detection levels for UK variant and Brazil variant - Clinical trials for Over-the-Counter at-home Testing completed, under FDA review INCHEON

JOB INFORMATION

Oversee global clinical trial operations (IND application, patient recruitment, and CRO management) Maintain and improve clinical trial quality (clinical trial provider monitoring, etc.)

ABOUT CELLTRION

About Us . A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. GENERIC CELLTRION PROJECT Efficiency improved through intra-group cooperation. For the success of the GCP, Celltrion Group has divided the tasks across two divisions. Celltrion Generic Business Division presides over the overall project, while Celltrion Pharm is responsible for research and production functions. DIATRUST™ COVID-19 AG RAPID TEST Celltrion DiaTrust™ COVID-19 Ag Rapid Test is a rapid test based on lateral flow immunoassay intended for the qualitative detection of nucleocapsid and receptor binding domains (RBDs) from the SARS-CoV-2 spike proteins in human nasopharyngeal swab specimen.

PERFORMANCE

보도자료 목록; Title Attached file Registration date; 1Q 2021 Earnings Release_Celltrion Inc. 2021.05.12: FY2020, 4Q20 Earning Release_Celltrion Inc.

DIATRUST™

Celltrion DiaTrust™ COVID-19 IgG/IgM Rapid Test is an in vitro diagnostic test based on an immunochromatographic assay. It is designed for qualitative detection of Immunoglobulin G and Immunoglobulin M antibodies of the novel Coronavirus (COVID-19) in PIPELINE | CELLTRION Celltrion will continue to blaze new trails and discover new opportunities. Project INN Original Major Indications Status Clinical Info; CT-P39: Omalizumab

SAMPINUTE™

Sampinute™ Analyzer (Immunoassay analyzer) Sampinute™ Analyzer detects specific biomarkers via immunoassay (MESIA; Magnetic Electrochemical Sandwich lmmunoassay) from a small amount of test sample. Sampinute™ Analyzer is intended to be used as an in vitro diagnostic medical device. Please read the user manual thoroughly for correct use and keep it for future reference.

INVESTOR INQUIRIES

1. General Statement . Celltrion, Inc. ("we", "us", "our" or "Celltrion") is committed to protecting and respecting your personal data. In the event that you send us any of your personal data, we are committed to collecting, maintaining, and securing personal data about you in accordance with our internal data protection policies and local

laws.

PRESS RELEASE

Celltrion DiaTrust™ COVID-19 Ag Rapid Test - Available for immediate supply - Expanded usage scope for use at the Point of Care(POC) and serial testing programs - Promising test sensitivity for COVID-19 variants with clinical data showing equivalent detection levels for UK variant and Brazil variant - Clinical trials for Over-the-Counter at-home Testing completed, under FDA review INCHEON

JOB INFORMATION

Oversee global clinical trial operations (IND application, patient recruitment, and CRO management) Maintain and improve clinical trial quality (clinical trial provider monitoring, etc.) PRODUCTS | CELLTRION Products. Celltrion’s products are available worldwide. home; PRODUCTS ; Bio pharmaceutical FINANCIALS | CELLTRION Financials. Accurate and transparent information about our business. home; IR ; Non-consolidated; Consolidated PIPELINE | CELLTRION Celltrion will continue to blaze new trails and discover new opportunities. Project INN Original Major Indications Status Clinical Info; CT-P39: Omalizumab TECHNOLOGY - CELLTRION The culture fluid completed 15 days of cell culture process contains antibodies that will become the active ingredients for finished pharmaceutical products, mixed up with other components such as cell debris, bacteria, and leftover media.

NEW FORMULATION

More Convenient Injection. Remsima SC is the first hypodermic injection-type Infliximab with enhanced convenience for patients. One of the significant issues with the original Infliximab is that it BIO BETTER | CELLTRION ADED Platform. The ADC bio better currently under development by Celltrion utilizes Antibody Delivery Enhancing Domain (ADED). This platform technology increases the delivery efficiency of the antibody-drug conjugates and their cell penetration, which greatly enhances treatments.

DIGITAL HEALTHCARE

Healthcare Data Integration Platform. Celltrion aims to develop disease prevention and management solutions for individuals by establishing a platform merged with healthcare data.

AUDIT·REVIEW

IR Documents. Information about our key performance indicators. home; IR ; Audit · Review Reports GOVERNANCE | CELLTRION 보도자료 게시판 목록으로 제목, 등록일에 대한 정보 제공; Name of Committee Internal Director Independent Director Main

Function

POWERPOINT

11 1% 13% 57% 36% 10% 0% 10% 20% 30% 40% 50% 60% q1 q2 q3 q4 q5 q6 q7 q8 q9 q10 q11 q12 q13 q14 q15 q16 q17 q18 q19 q20 remsima truxima herzuma 57% 38% 5% remsima remicade a's CELLTRIONTRANSLATE THIS PAGE Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

ABOUT CELLTRION

About Us. A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans

to follow up by

CELLTRIONTRANSLATE THIS PAGE Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

DIATRUST™ COVID-19 AG RAPID TEST Celltrion DiaTrust™ COVID-19 Ag Rapid Test is a rapid test based on lateral flow immunoassay intended for the qualitative detection of nucleocapsid and receptor binding domains (RBDs) from the SARS-CoV-2 spike proteins in human nasopharyngeal swab specimen. Results are for the identification of SARS-CoV-2 nucleocapsid and RBD protein antigen.

PERFORMANCE

보도자료 목록; Title Attached file Registration date; 1Q 2021 Earnings Release_Celltrion Inc. 2021.05.12: FY2020, 4Q20 Earning Release_Celltrion Inc. GENERIC CELLTRION PROJECT The global generic market, which takes up two-thirds of the global pharmaceutical market, is expected to reach a total market worth of 833 billion dollars by 2021. In recognition of this potential for market growth, Celltrion created the Global Chemical Development Division to strengthen our position in the global pharmaceutical

market.

FINANCIALS | CELLTRION Financials. Accurate and transparent information about our business. home; IR ; Non-consolidated; Consolidated

SAMPINUTE™

Sampinute™ Analyzer (Immunoassay analyzer) Sampinute™ Analyzer detects specific biomarkers via immunoassay (MESIA; Magnetic Electrochemical Sandwich lmmunoassay) from a small amount of test sample. Sampinute™ Analyzer is intended to be used as an in vitro diagnostic medical device. Please read the user manual thoroughly for correct use and keep it for future reference. CELLTRIONTRANSLATE THIS PAGE Celltrion. Embrace Life. 글로벌 헬스케어 리딩기업 셀트리온. 인류의 더 건강하고 행복한 삶을 위한 우리의 도전은 계속됩니다. CELLTRION - 셀트리온 채용사이트TRANSLATE THIS PAGE 채용문의. 셀트리온제약 채용관련 문의드립니다. 서류전형 결과 관련 문의. 21년 상반기 채용관련 질문드립니다. 비밀번호 찾기. 자주묻는 질문. 전형결과 확인. 인재상. 지원서 작성. CELLTRIONTRANSLATE THIS PAGE Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

ABOUT CELLTRION

About Us. A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans

to follow up by

CELLTRIONTRANSLATE THIS PAGE Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

DIATRUST™ COVID-19 AG RAPID TEST Celltrion DiaTrust™ COVID-19 Ag Rapid Test is a rapid test based on lateral flow immunoassay intended for the qualitative detection of nucleocapsid and receptor binding domains (RBDs) from the SARS-CoV-2 spike proteins in human nasopharyngeal swab specimen. Results are for the identification of SARS-CoV-2 nucleocapsid and RBD protein antigen.

PERFORMANCE

보도자료 목록; Title Attached file Registration date; 1Q 2021 Earnings Release_Celltrion Inc. 2021.05.12: FY2020, 4Q20 Earning Release_Celltrion Inc. GENERIC CELLTRION PROJECT The global generic market, which takes up two-thirds of the global pharmaceutical market, is expected to reach a total market worth of 833 billion dollars by 2021. In recognition of this potential for market growth, Celltrion created the Global Chemical Development Division to strengthen our position in the global pharmaceutical

market.

FINANCIALS | CELLTRION Financials. Accurate and transparent information about our business. home; IR ; Non-consolidated; Consolidated

SAMPINUTE™

Sampinute™ Analyzer (Immunoassay analyzer) Sampinute™ Analyzer detects specific biomarkers via immunoassay (MESIA; Magnetic Electrochemical Sandwich lmmunoassay) from a small amount of test sample. Sampinute™ Analyzer is intended to be used as an in vitro diagnostic medical device. Please read the user manual thoroughly for correct use and keep it for future reference. CELLTRIONTRANSLATE THIS PAGE Celltrion. Embrace Life. 글로벌 헬스케어 리딩기업 셀트리온. 인류의 더 건강하고 행복한 삶을 위한 우리의 도전은 계속됩니다. CELLTRION - 셀트리온 채용사이트TRANSLATE THIS PAGE 채용문의. 셀트리온제약 채용관련 문의드립니다. 서류전형 결과 관련 문의. 21년 상반기 채용관련 질문드립니다. 비밀번호 찾기. 자주묻는 질문. 전형결과 확인. 인재상. 지원서 작성. CELLTRIONTRANSLATE THIS PAGE Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

FINANCIALS | CELLTRION Financials. Accurate and transparent information about our business. home; IR ; Non-consolidated; Consolidated

PERFORMANCE

보도자료 목록; Title Attached file Registration date; 1Q 2021 Earnings Release_Celltrion Inc. 2021.05.12: FY2020, 4Q20 Earning Release_Celltrion Inc. PRODUCTS | CELLTRION Products. Celltrion’s products are available worldwide. home; PRODUCTS ; Bio pharmaceutical PIPELINE | CELLTRION Celltrion will continue to blaze new trails and discover new opportunities. Project INN Original Major Indications Status Clinical Info; CT-P39: Omalizumab

DIATRUST™

Celltrion DiaTrust™ COVID-19 IgG/IgM Rapid Test is an in vitro diagnostic test based on an immunochromatographic assay. It is designed for qualitative detection of Immunoglobulin G and Immunoglobulin M antibodies of the novel Coronavirus (COVID-19) in GOVERNANCE | CELLTRION KAIST (PH.D.) (Current) Chairman of BOD, Celltrion inc. (Former) Vice President of Product Development, Celltrion inc. (Former) CEO, Celltrion Skincure inc. (Former) General Executive Director, Celltrion Skincure inc. (Former) Representative of Biotechnological Laboratory

1, Celltrion inc.

DIGITAL HEALTHCARE

Celltrion aims to develop disease prevention and management solutions for individuals by establishing a platform merged with healthcare data. Celltrion’s Digital Healthcare business focuses on creating a patient-centered environment by using health information from the newest ICT technologies and services. Celltrion works close with

Ground X

JOB INFORMATION

Oversee global clinical trial operations (IND application, patient recruitment, and CRO management) Maintain and improve clinical trial quality (clinical trial provider monitoring, etc.) CELLTRION - 셀트리온 채용사이트TRANSLATE THIS PAGE 채용문의. 셀트리온제약 채용관련 문의드립니다. 서류전형 결과 관련 문의. 21년 상반기 채용관련 질문드립니다. 비밀번호 찾기. 자주묻는 질문. 전형결과 확인. 인재상. 지원서 작성.

ABOUT CELLTRION

About Us. A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans

to follow up by

CELLTRIONABOUT USBUSINESSSCIENCEPRODUCTSIRPR Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

DIATRUST™ COVID-19 AG RAPID TESTRAPID ANTIGEN DETECTION TESTRAPID ANTIGEN TEST ACCURACYRAPID ANTIGEN TEST MARYLANDRAPID ANTIGEN TESTS Celltrion DiaTrust™ COVID-19 Ag Rapid Test is a rapid test based on lateral flow immunoassay intended for the qualitative detection of nucleocapsid and receptor binding domains (RBDs) from the SARS-CoV-2 spike proteins in human nasopharyngeal swab specimen. Results are for the identification of SARS-CoV-2 nucleocapsid and RBD protein antigen. FINANCIALS | CELLTRION Financials. Accurate and transparent information about our business. home; IR ; Non-consolidated; Consolidated

PERFORMANCE

보도자료 목록; Title Attached file Registration date; 1Q 2021 Earnings Release_Celltrion Inc. 2021.05.12: FY2020, 4Q20 Earning Release_Celltrion Inc. GENERIC CELLTRION PROJECT The global generic market, which takes up two-thirds of the global pharmaceutical market, is expected to reach a total market worth of 833 billion dollars by 2021. In recognition of this potential for market growth, Celltrion created the Global Chemical Development Division to strengthen our position in the global pharmaceutical

market.

DIATRUST™

Celltrion DiaTrust™ COVID-19 IgG/IgM Rapid Test is an in vitro diagnostic test based on an immunochromatographic assay. It is designed for qualitative detection of Immunoglobulin G and Immunoglobulin M antibodies of the novel Coronavirus (COVID-19) in

SAMPINUTE™

Sampinute™ Analyzer (Immunoassay analyzer) Sampinute™ Analyzer detects specific biomarkers via immunoassay (MESIA; Magnetic Electrochemical Sandwich lmmunoassay) from a small amount of test sample. Sampinute™ Analyzer is intended to be used as an in vitro diagnostic medical device. Please read the user manual thoroughly for correct use and keep it for future reference.

JOB INFORMATION

Oversee global clinical trial operations (IND application, patient recruitment, and CRO management) Maintain and improve clinical trial quality (clinical trial provider monitoring, etc.) CELLTRION - 셀트리온 채용사이트 채용문의. 셀트리온제약 채용관련 문의드립니다. 서류전형 결과 관련 문의. 21년 상반기 채용관련 질문드립니다. 비밀번호 찾기. 자주묻는 질문. 전형결과 확인. 인재상. 지원서 작성.

ABOUT CELLTRION

About Us. A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans

to follow up by

CELLTRIONABOUT USBUSINESSSCIENCEPRODUCTSIRPR Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

DIATRUST™ COVID-19 AG RAPID TESTRAPID ANTIGEN DETECTION TESTRAPID ANTIGEN TEST ACCURACYRAPID ANTIGEN TEST MARYLANDRAPID ANTIGEN TESTS Celltrion DiaTrust™ COVID-19 Ag Rapid Test is a rapid test based on lateral flow immunoassay intended for the qualitative detection of nucleocapsid and receptor binding domains (RBDs) from the SARS-CoV-2 spike proteins in human nasopharyngeal swab specimen. Results are for the identification of SARS-CoV-2 nucleocapsid and RBD protein antigen. FINANCIALS | CELLTRION Financials. Accurate and transparent information about our business. home; IR ; Non-consolidated; Consolidated

PERFORMANCE

보도자료 목록; Title Attached file Registration date; 1Q 2021 Earnings Release_Celltrion Inc. 2021.05.12: FY2020, 4Q20 Earning Release_Celltrion Inc. GENERIC CELLTRION PROJECT The global generic market, which takes up two-thirds of the global pharmaceutical market, is expected to reach a total market worth of 833 billion dollars by 2021. In recognition of this potential for market growth, Celltrion created the Global Chemical Development Division to strengthen our position in the global pharmaceutical

market.

DIATRUST™

Celltrion DiaTrust™ COVID-19 IgG/IgM Rapid Test is an in vitro diagnostic test based on an immunochromatographic assay. It is designed for qualitative detection of Immunoglobulin G and Immunoglobulin M antibodies of the novel Coronavirus (COVID-19) in

SAMPINUTE™

Sampinute™ Analyzer (Immunoassay analyzer) Sampinute™ Analyzer detects specific biomarkers via immunoassay (MESIA; Magnetic Electrochemical Sandwich lmmunoassay) from a small amount of test sample. Sampinute™ Analyzer is intended to be used as an in vitro diagnostic medical device. Please read the user manual thoroughly for correct use and keep it for future reference.

JOB INFORMATION

Oversee global clinical trial operations (IND application, patient recruitment, and CRO management) Maintain and improve clinical trial quality (clinical trial provider monitoring, etc.) CELLTRION - 셀트리온 채용사이트 채용문의. 셀트리온제약 채용관련 문의드립니다. 서류전형 결과 관련 문의. 21년 상반기 채용관련 질문드립니다. 비밀번호 찾기. 자주묻는 질문. 전형결과 확인. 인재상. 지원서 작성.

CELLTRION

Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

CELLTRION

Celltrion. Embrace Life. Global healthcare leader Celltrion will continue. its innovation to promote better and happier lives. for

humanity.

PRODUCTS | CELLTRION Products. Celltrion’s products are available worldwide. home; PRODUCTS ; Bio pharmaceutical

PERFORMANCE

보도자료 목록; Title Attached file Registration date; 1Q 2021 Earnings Release_Celltrion Inc. 2021.05.12: FY2020, 4Q20 Earning Release_Celltrion Inc. PIPELINE | CELLTRION Celltrion will continue to blaze new trails and discover new opportunities. Project INN Original Major Indications Status Clinical Info; CT-P39: Omalizumab

DIGITAL HEALTHCARE

Celltrion aims to develop disease prevention and management solutions for individuals by establishing a platform merged with healthcare data. Celltrion’s Digital Healthcare business focuses on creating a patient-centered environment by using health information from the newest ICT technologies and services. Celltrion works close with

Ground X

CELLTRION

Celltrion. Embrace Life. 글로벌 헬스케어 리딩기업 셀트리온. 인류의 더 건강하고 행복한 삶을 위한 우리의 도전은 계속됩니다.

INVESTOR INQUIRIES

1. General Statement . Celltrion, Inc. ("we", "us", "our" or "Celltrion") is committed to protecting and respecting your personal data. In the event that you send us any of your personal data, we are committed to collecting, maintaining, and securing personal data about you in accordance with our internal data protection policies and local

laws.

PRESS RELEASE

Press Release. Our latest news, provided in real time. home; PR ;

등록일

AUDIT·REVIEW

IR Documents. Information about our key performance indicators. home; IR ; Audit · Review Reports 주 메뉴 바로가기 본문 바로가기 하단 바로가기

CELLTRION

gnb메뉴보기

ENG

* KOR

* ENG

* CHN

* ABOUT US

* Company

* About Celltrion

* History

* CI

* Leadership

* Chairman Message

* CEO Message

* Responsibility

* Contact Us

* BUSINESS

* Biosimilar

* Autoimmune Disease

* Anti-Cancer Drug

* Small molecules

* Generic Celltrion Project

* New Medicines

* New Formulation

* Bio Better

* New Drugs

* U-Healthcare

* Vision 2030

* SCIENCE

* R&D

* Research Center

* Fields of Research

* R&D STORY

* Pipeline

* Technology

* PRODUCTS

* Products

* Manufacturing

* Quality

* Facilities

* Production Process

* IR

* Financials

* IR Documents

* Performance

* Audit·Review

* Governance

* PR

* Notice

* Press Release

* PR Materials

* Video

* Digital Brochures

* Images

* CAREERS

* Talents

* Employment

*

* Recruiting Process

* Job Information

* Welfare

* Zoom in Celltrion

Gnb 메뉴 닫기

Pioneering into the

future

Celltrion has shifted the pharmaceutical paradigm with outstanding biopharmaceutical products, Research and Development capabilities, and expertise

Learn more

다음 페이지 이동

Embrace Life

Global healthcare leader Celltrion will continue its innovation to promote better and happier lives

for humanity

다음 페이지 이동

Biologics

that are more approachable Celltrion's antibody biosimilars provide patients with high-quality yet affordable

Learn more

다음 페이지 이동 Pharmaceuticalsreinnovated By venturing into the $833 billion global pharmaceutical market, we are excited to provide affordable healthcare for more patients

around the world

Learn more

다음 페이지 이동

Pioneering into the

future

Celltrion has shifted the pharmaceutical paradigm with outstanding biopharmaceutical products, Research and Development capabilities, and expertise

Learn more

다음 페이지 이동

Embrace Life

Global healthcare leader Celltrion will continue its innovation to promote better and happier lives

for humanity

다음 페이지 이동

정지

* Legal Notice

* Privacy Notice

* Export and Import Management Policy * Internal Information Control Regulation

*

* Contact Us

* Directions

* 인천광역시 연수구아카데미로 23

* 032-850-5000

COPYRICHT © 2019 CELLTRION INC. ALL RIGHTS RESERVED.

*

*

*

*

Family site __

* Celltrion

* 셀트리온헬스케어

* Celltrion Pharm

* 셀트리온스킨큐어 * 셀트리온복지재단

Brand site __

* 램시마

* 트룩시마

* 허쥬마